Chemotherapy Strategies in Metastatic Pancreatic Ductal Adenocarcinoma (PDAC)
Eileen O’Reilly, MD
Efrat Dotan, MD
Mutational Testing in mCRC: Methods and Data Driving Treatment Selection
Fortunato Ciardiello, MD, PhD
Jenny Seligmann, MBChB, PhD
Defining the Standard of Care and Optimal Sequencing in BRAF-Mutant mCRC: Second Line and Beyond
Reviewing the Latest Bladder Cancer Practice Guidelines
Elizabeth R. Plimack, MD, MS, FASCO
Exploring New and Emerging Treatments in Muscle Invasive Bladder Cancer
Patient Perspectives on Bladder Cancer
Lillibeth Velasco, MSN, RN
Understanding the Expanding Role of Antibody-Drug Conjugates in Bladder Cancer
Metastatic Pancreatic Ductal Adenocarcinoma (PDAC): From Diagnosis to Treatment
Shubham Pant, MD, MBBS
Immunotherapy for TNBC in the Perioperative Setting: Clinical Evidence and Considerations
Peter Schmid, FRCP, MD, PhD
Applying Current Guidelines in the First-Line Treatment of MSI-H/dMMR mCRC—A Case Discussion
Aparna R. Parikh, MD
Clinical Implications of Current Guidelines on First-Line Immunotherapy and PARP Inhibitors for TNBC
Biomarker-Directed Approaches for Frontline Treatment of Advanced Gastric/GEJ Cancers: The Evidence
Sara Lonardi, MD
Current Guideline Recommendations for Biomarker-Based Second-Line Treatment of mCRC
Management of HER2-Low MBC Following First-Line Disease Progression
Expert Opinion: Key Insights on GI Malignancies—Integrating NCCN Clinical Practice Guidelines Into Practice
Alan Venook, MD
Guideline Recommendations for the Definition and Treatment of HER2-Low Breast Cancer
Erica L. Mayer, MD, MPH
Loading...
NEW FEATURES:
Tell us what you think by using the Feedback button on the right side of the page.
We're glad to see you're enjoying Global Oncology Academy… but how about a more personalized experience?
Press cancel to remain on Global Oncology Academy. Press the link below or the continue button to keep going.